Clinical Trials in Rivne, Ukraine
7 recruiting
Showing 1–15 of 15 trials
Recruiting
Phase 2
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
Primary Membranous Nephropathy
Climb Bio, Inc.45 enrolled45 locationsNCT07096843
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Rectal AdenocarcinomaColon Adenocarcinoma
Merck Sharp & Dohme LLC477 enrolled161 locationsNCT06997497
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC675 enrolled145 locationsNCT07190248
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled215 locationsNCT06345729
Recruiting
Phase 3
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC400 enrolled16 locationsNCT07431827
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer444 enrolled283 locationsNCT06452277
Recruiting
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Merck Sharp & Dohme LLC1,065 enrolled47 locationsNCT04165798
Recruiting
Phase 2
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Lung Neoplasm Malignant
Merck Sharp & Dohme LLC60 enrolled34 locationsNCT06788912
Recruiting
Phase 1Phase 2
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Merck Sharp & Dohme LLC450 enrolled46 locationsNCT04165070
Recruiting
Phase 3
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
Chronic Hepatitis D Infection
Mirum Pharmaceuticals, Inc.80 enrolled27 locationsNCT07298330
Recruiting
Not Applicable
Neuroma-Associated Pain Management After Combat-Related Trauma in Ukraine
Quality of LifePain ManagementDepression in Adults+4 more
Ukrainian Society of Regional Anesthesia and Pain Therapy50 enrolled1 locationNCT07416448
Recruiting
Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Advanced Solid Tumors
Merck Sharp & Dohme LLC830 enrolled73 locationsNCT05067283
Recruiting
Not Applicable
Comprehensive Multicenter Study on the Management of Acute Pain Following Thoracic Combat-Related Trauma in Ukraine
Quality of LifePain ManagementPulmonary Function+5 more
Lviv National Medical University50 enrolled1 locationNCT07380789
Recruiting
Phase 3
Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID)
Primary Immunodeficiency Diseases
Biopharma Plasma LLC56 enrolled12 locationsNCT07346859
Recruiting
Phase 4
Human Anti-D (rh) Immunoglobulin (Rhesoglobin) Efficacy, Safety and Some Pharmacokinetics Parameters in Pregnant Women
Pregnancy Related
Biopharma Plasma LLC281 enrolled16 locationsNCT05245734